Plasma amyloid-β in patients with Tangier disease.

J Alzheimers Dis 2013 ;35(2):307-12

Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Neurochemistry, Sahlgrenska University Hospital/Mölndal, Sweden.

Tangier disease (TD) is a rare genetic disorder caused by mutations in the ATP-binding cassette transporter A1 (ABCA1) gene, which results in impaired cellular cholesterol efflux and high-density lipoprotein cholesterol deficiency. Animal and in vitro studies indicate that ABCA1 is involved in the production of amyloid-β (Aβ), a pivotal protein in Alzheimer's disease. We here examined whether plasma Aβ levels are altered in TD patients. Plasma from 5 TD patients and 5 controls were analyzed for Aβ1-40, Aβ1-42, AβX-40, and AβX-42 but no differences were found. In conclusion, loss of ABCA1 function may not have any profound effect on Aβ metabolism in humans, at least not in the periphery, as reflected by plasma Aβ levels.

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-122425DOI Listing
October 2013
3 Reads

Publication Analysis

Top Keywords

plasma aβ
8
aβ levels
8
tangier disease
8
studies indicate
4
aβx-42 differences
4
indicate abca1
4
abca1 involved
4
4
production amyloid-β
4
involved production
4
plasma
4
vitro studies
4
cholesterol deficiency
4
loss abca1
4
high-density lipoprotein
4
conclusion loss
4
deficiency animal
4
differences conclusion
4
animal vitro
4
amyloid-β aβ
4

Similar Publications